Bain Capital Life Sciences Investors’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-4,702,996	Closed	-$19.8M	–	35
2023 Q1	$19.8M	Buy	4,702,996 +925,688	+25%	+$4.8M	2.47%	14
2022 Q4	$22.7M	Buy	+3,777,308	New	+$20.6M	2.54%	14

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Bain Capital Life Sciences Investors's CTIC Position: Q2 2023 in Review

Bain Capital Life Sciences Investors sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 4,702,996 shares — an estimated $19.8M sold.

Bain Capital Life Sciences Investors first reported a position in CTIC in Q4 2022 and held it in 2 quarters. The position peaked at $22.7M in Q4 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

Bain Capital Life Sciences Investors reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
Bain Capital Life Sciences Investors sold 4,702,996 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $19.8M.
Bain Capital Life Sciences Investors first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2022 and held it in 2 quarters.
Bain Capital Life Sciences Investors's CTI BioPharma Corp. (DE) Common Stock position peaked at $22.7M in Q4 2022.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Bain Capital Life Sciences Investors's 13F filing for Q2 2023, filed 14 Aug 2023.